Cabrellis Pharmaceuticals Corporation Announces Corporate Launch and Founding Management Team.SAN DIEGO San Diego (săn dēā`gō), city (1990 pop. 1,110,549), seat of San Diego co., S Calif., on San Diego Bay; inc. 1850. San Diego includes the unincorporated communities of La Jolla and Spring Valley. Coronado is across the bay. -- Cabrellis Pharmaceuticals Corporation today announced the formal launch of operations following a successful spinout spin·out n. An instance of spinning out: a motorist who was injured in a spinout. from Conforma Therapeutics Corporation. The company was formed by members of the Conforma management team that executed the sale of Conforma to Biogen Idec, Inc. earlier this month. Cabrellis is a specialty pharmaceutical company committed to the development of therapies for the treatment of cancer. The Company's lead product, Calsed(TM) (amrubicin hydrochloride hydrochloride /hy·dro·chlo·ride/ (-klor´id) a salt of hydrochloric acid. hy·dro·chlo·ride n. A compound resulting from the reaction of hydrochloric acid with an organic base. ), is expected to enter Phase II clinical testing later this quarter. "Conforma and its investors have always felt very strongly about the promise and potential of Calsed(TM)," said Thomas M. Estok, president and chief executive officer of Cabrellis. "Our enthusiasm led directly to this opportunity to create Cabrellis and to continue the development of Calsed(TM) ourselves. We plan to aggressively and broadly advance Calsed(TM) through clinical development and expand our anti-cancer portfolio via strategic licensing." Cabrellis' initial investors will be comprised of the former Conforma shareholders, including Domain Associates, Forward Ventures, Lilly Ventures, Novo A/S, ProQuest Investments, RBC RBC red blood cell. RBC or rbc abbr. red blood cell RBC, n See red blood cell count. RBC red blood cells; red blood (cell) count (see blood count). Capital Partners, RiverVest Venture Partners, and S.R. One, Limited. Mr. Estok will be joined by co-founders John E. Crawford, who will serve as chief financial and administrative officer, and Christopher C. LeMasters, who will serve as chief business officer. Both were former officers with Conforma Therapeutics. "Cabrellis is fortunate to have a strong partner in Dainippon Sumitomo Pharma," said Christopher LeMasters. "Since the inception of the partnership with Conforma in June of 2005, they have been extraordinarily supportive. Both of our companies are looking forward to continuing this successful relationship." About Calsed(TM) Calsed(TM) (amrubicin hydrochloride) is a third generation, totally synthetic anticancer drug anticancer drug see antineoplastic. anticancer drug Chemotherapeutic, see there . In pre-clinical studies, amrubicin demonstrated a higher level of anti-tumor activity than conventional anthracycline drugs without exhibiting any indication of the cumulative cardiac toxicity common to this class of compounds. In clinical trials conducted in Japan, Calsed(TM) has been proven to be effective in patients with small cell lung cancer Lung Cancer, Small Cell Definition Small cell lung cancer is a disease in which the cells of the lung tissues grow uncontrollably and form tumors. Description Lung cancer is divided into two main types: small cell and non-small cell. as well as non-small cell lung cancer Lung Cancer, Non-Small Cell Definition Non-small cell lung cancer (NSCLC) is a disease in which the cells of the lung tissues grow uncontrollably and form tumors. Description There are two kinds of lung cancers, primary and secondary. . Dainippon Sumitomo launched Calsed(TM) in Japan in December 2002 and the drug has been administered to over 6000 patients without any reports of cumulative cardiotoxicity to date. Dainippon Sumitomo is conducting additional Calsed(TM) clinical trials in Japan in lung cancer lung cancer, cancer that originates in the tissues of the lungs. Lung cancer is the leading cause of cancer death in the United States in both men and women. Like other cancers, lung cancer occurs after repeated insults to the genetic material of the cell. and Non-Hodgkin's Lymphoma non-Hodg·kin's lymphoma n. Any of various malignant lymphomas characterized by the absence of Reed-Sternberg cells. Non-Hodgkin's lymphoma . Calsed(TM) is marketed in Japan as an injectable freeze-dried preparation, indicated for use in both non-small cell and small cell lung cancers. Cabrellis has the exclusive rights to develop and commercialize Calsed(TM) in North America and Europe, licensed from Dainippon Sumitomo Pharma of Osaka, Japan. About Cabrellis Pharmaceuticals Cabrellis is a specialty pharmaceutical company committed to the development of therapies for the treatment of cancer. The Company's lead product, Calsed(TM) (amrubicin), is a third generation anthracycline and the world's first totally synthetic anthracycline drug, licensed from Dainippon Sumitomo Pharma. Further information regarding Cabrellis is available at www.cabrellis.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion